All In Biotech

Drug Trial Radar · NCT07521657

Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma

Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

55

Planned (sponsor's estimate)

Start

Jan 1, 2027

Primary completion

Jan 1, 2031

Study completion Jan 1, 2032

Sponsor

Lead sponsor
University of Alabama at BirminghamAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Children's Hospital of Philadelphia; Congressionally Directed Medical Research Programs
First posted
Apr 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 89 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 2, open label, parallel multi-arm study of mirdametinib in combination with radiation in participants with recurrent sporadic glioblastoma (GBM) harboring NF1 alterations (Cohort 1); participants with NF1 with a newly diagnosed GBM (Cohort 2); mirdametinib alone in other NF1-associated High-Grade Gliomas (Cohort 3).

Conditions

  • Neurofibromatosis 1 (NF1)

Interventions

  • mirdametinib with radiationCombination product

    Participants in Cohorts 1 and 2 will receive mirdametinib in combination with radiation therapy followed by mirdametinib alone.

  • mirdametinibDrug

    Participants in Cohort 3 will receive mirdametinib alone.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohort 1Time frame: From treatment to 12 months
  2. Cohort 2Time frame: From treatment to 18 months
  3. Cohort 3Time frame: From treatment to 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Childrens of Alabama

    Birmingham, Alabama

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.